Payload ID	PAY0LEIGJ
Name	Exatecan
Synonyms	Exatecan; 171335-80-1; Exatecan [INN]; Exatecan mesylate; DX-8951; DX-8951f; OC71PP0F89; (1S,9S)-1-Amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10H,13H-benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-10,13-dione; Dx 8951; UNII-OC71PP0F89; exatecan-mesylate; (1s,9s)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10h,13h-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione; EXATECAN [MI]; EXATECAN [WHO-DD]; SCHEMBL2512959; CHEMBL1614650; DTXSID60169061; CHEBI:135709; EX-A2683; NSC829066; AKOS005146469; AT33978; BCP9000674; DB12185; NSC-829066; 10H,13H-Benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-; 10H,13H-Benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S-trans)-; AC-32495; BP-27995; BP-27996; HY-13631; DB-064817; DX8951;DX 8951;DX-8951; J-521361; Q5419343; (10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaene-5,9-dione; (1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-2,3,12,15-tetrahydrobenzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(1H,9H)-dione    Click to Show/Hide
Target	DNA topoisomerase 1 (TOP1)					Target Info
Structure
	3D MOL			2D MOL
Formula	C24H22FN3O4
Isosmiles	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C5[C@H](CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)N)O
PubChem CID	151115
InChI	InChI=1S/C24H22FN3O4/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19/h6-7,16,31H,3-5,8-9,26H2,1-2H3/t16-,24-/m0/s1
InChIKey	ZVYVPGLRVWUPMP-FYSMJZIKSA-N
IUPAC Name	(10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaene-5,9-dione
Pharmaceutical Properties	Molecule Weight		435.4	Polar area		106
	Complexity		950	xlogp Value		0.4
	Heavy Count		32	Rot Bonds		1
	Hbond acc		7	Hbond Donor		2

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Half Maximal Inhibitory Concentration (IC50)	0.16	nM	MOLT-4 cells	Adult T acute lymphoblastic leukemia	CVCL_0013	[1]
Half Maximal Inhibitory Concentration (IC50)	0.25	nM	CCRF-CEM cells	T acute lymphoblastic leukemia	CVCL_0207	[1]
Half Maximal Inhibitory Concentration (IC50)	0.49	nM	DU145 cells	Prostate carcinoma	CVCL_0105	[1]
Half Maximal Inhibitory Concentration (IC50)	0.58	nM	DMS 114 cells	Lung small cell carcinoma	CVCL_1174	[1]

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Progression Free Survival	5.3 months
Patients Enrolled	Inclusion criteria: Adults (≥18) with ECOG 0-1, adequate organ function, and measurable lesions (RECIST 1.1), stratified by tumor type (Phase Ia: solid tumors; Phase Ib: G/GEJ AC, PDAC, BTC with CLDN18.2 positivity). Exclusions: recent anticancer therapy (<4 weeks), uncontrolled infections, major surgery (<4 weeks), CNS metastases, HIV/HBV/HCV, cardiovascular risks, bowel obstruction, or prior allogeneic transplants. Pregnancy and prior severe allergies to monoclonal antibodies are excluded.    Click to Show/Hide
Administration Dosage	IBI343 will be administered intravenously (IV) on Day 1 of every 21-day cycle.
Related Clinical Trial
NCT Number	NCT05458219	Phase Status	PHASE1
Clinical Description	A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Primary Endpoint	The study evaluates safety through adverse events (AEs), treatment-emergent AEs (TEAEs), serious AEs (SAEs) assessed via NCI-CTCAE v5.0 over 90 days post-treatment, and dose-limiting toxicities (DLTs) monitored for 21 days post-first dose to determine MTD/RP2D. Efficacy is measured via investigator-assessed ORR per RECIST 1.1, tracking CR/PR rates over 2 years.    Click to Show/Hide
Other Endpoint	Pharmacokinetic parameters include Cmax, AUC, CL, t1/2, V, Tmax, and Ctrough of IBI343 over 2 years, alongside anti-drug antibody (ADA) incidence. Efficacy outcomes feature ORR, TTR (time to first CR/PR), DoR (response duration until PD/death), DCR (CR/PR/SD rates), PFS (time to progression/death), and OS (time to death from any cause) assessed over 2 years (OS: 1 year average).    Click to Show/Hide
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Objective Response Rate (ORR)	24.40%
Patients Enrolled	Inclusion criteria: Adults (≥18) with ECOG 0-1, adequate organ function, and measurable lesions (RECIST 1.1), stratified by tumor type (Phase Ia: solid tumors; Phase Ib: G/GEJ AC, PDAC, BTC with CLDN18.2 positivity). Exclusions: recent anticancer therapy (<4 weeks), uncontrolled infections, major surgery (<4 weeks), CNS metastases, HIV/HBV/HCV, cardiovascular risks, bowel obstruction, or prior allogeneic transplants. Pregnancy and prior severe allergies to monoclonal antibodies are excluded.    Click to Show/Hide
Administration Dosage	IBI343 will be administered intravenously (IV) on Day 1 of every 21-day cycle.
Related Clinical Trial
NCT Number	NCT05458219	Phase Status	PHASE1
Clinical Description	A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Primary Endpoint	The study evaluates safety through adverse events (AEs), treatment-emergent AEs (TEAEs), serious AEs (SAEs) assessed via NCI-CTCAE v5.0 over 90 days post-treatment, and dose-limiting toxicities (DLTs) monitored for 21 days post-first dose to determine MTD/RP2D. Efficacy is measured via investigator-assessed ORR per RECIST 1.1, tracking CR/PR rates over 2 years.    Click to Show/Hide
Other Endpoint	Pharmacokinetic parameters include Cmax, AUC, CL, t1/2, V, Tmax, and Ctrough of IBI343 over 2 years, alongside anti-drug antibody (ADA) incidence. Efficacy outcomes feature ORR, TTR (time to first CR/PR), DoR (response duration until PD/death), DCR (CR/PR/SD rates), PFS (time to progression/death), and OS (time to death from any cause) assessed over 2 years (OS: 1 year average).    Click to Show/Hide
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Disease control rate (DCR)	80.50%
Patients Enrolled	Inclusion criteria: Adults (≥18) with ECOG 0-1, adequate organ function, and measurable lesions (RECIST 1.1), stratified by tumor type (Phase Ia: solid tumors; Phase Ib: G/GEJ AC, PDAC, BTC with CLDN18.2 positivity). Exclusions: recent anticancer therapy (<4 weeks), uncontrolled infections, major surgery (<4 weeks), CNS metastases, HIV/HBV/HCV, cardiovascular risks, bowel obstruction, or prior allogeneic transplants. Pregnancy and prior severe allergies to monoclonal antibodies are excluded.    Click to Show/Hide
Administration Dosage	IBI343 will be administered intravenously (IV) on Day 1 of every 21-day cycle.
Related Clinical Trial
NCT Number	NCT05458219	Phase Status	PHASE1
Clinical Description	A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Primary Endpoint	The study evaluates safety through adverse events (AEs), treatment-emergent AEs (TEAEs), serious AEs (SAEs) assessed via NCI-CTCAE v5.0 over 90 days post-treatment, and dose-limiting toxicities (DLTs) monitored for 21 days post-first dose to determine MTD/RP2D. Efficacy is measured via investigator-assessed ORR per RECIST 1.1, tracking CR/PR rates over 2 years.    Click to Show/Hide
Other Endpoint	Pharmacokinetic parameters include Cmax, AUC, CL, t1/2, V, Tmax, and Ctrough of IBI343 over 2 years, alongside anti-drug antibody (ADA) incidence. Efficacy outcomes feature ORR, TTR (time to first CR/PR), DoR (response duration until PD/death), DCR (CR/PR/SD rates), PFS (time to progression/death), and OS (time to death from any cause) assessed over 2 years (OS: 1 year average).    Click to Show/Hide
Experiment 4 Reporting the Activity Date of This ADC					[3]
Patients Enrolled	Inclusion: Adults (≥18) with CLDN18.2-positive unresectable/metastatic pancreatic adenocarcinoma (confirmed histopathology, measurable lesions per RECIST 1.1), ECOG 0-1, life expectancy ≥12 weeks, adequate organ function. Prior systemic therapy allowed in Part 1 but prohibited in Part 2 (treatment-naïve population). Exclusion: Recent anti-tumor therapy (within 4 weeks), CYP3A4 inhibitors (2 weeks/5 half-lives), untreated CNS metastases, gastrointestinal perforation/fistula (6 months), interstitial lung disease, prior topoisomerase inhibitor ADCs, pregnancy, or conditions contraindicating study participation. Palliative radiotherapy/surgery is permitted under specific conditions.    Click to Show/Hide
Administration Dosage	There are two parts in this study, Part1 (safe lead-in phase) and Part2 (extension phase). In part1, patients with CLDN18.2-positive advanced pancreatic adenocarcinoma who had or had not previously received systemic therapy will be enrolled. The starting dose of the AG regimen was albumin-paclitaxel 100mg / m2 combined with gemcitabine 800mg / m2 by intravenous infusion (Intravenous, IV) D1 and D8 Q3W. If none of the first 3 subjects at 6 mg / kg had DLT during the DLT observation period, the combined high dose AG regimen was attempted. The investigator will adjust the dose of IBI343 combination chemotherapy according to the previous safety results and determine the safety of the combination dose, then entering the Part 2.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT06770439	Phase Status	PHASE2
Clinical Description	A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI343 Combined with Chemotherapy in Advanced Pancreatic Cancer
Primary Endpoint	The study evaluates the primary efficacy endpoint of Objective Response Rate (ORR per RECIST 1.1) and key safety measures including adverse events (hematotoxicity, hepatotoxicity, renal function) assessed via CTCAE 5.0 over 2 years.
Other Endpoint	Secondary endpoints include Progression-Free Survival (PFS), Duration of Response (DOR), Disease Control Rate (DCR, incorporating PR/SD), Time to Response (TTR), and Overall Survival (OS) - all measured over 2 years to assess long-term clinical outcomes.
Experiment 5 Reporting the Activity Date of This ADC					[4]
Patients Enrolled	Key inclusion criteria involve signing informed consent, confirmed unresectable locally advanced or metastatic G/GEJ adenocarcinoma, CLDN18.2-positive status, ≥18 years old, ECOG PS 0-1, and progression after ≥2 prior systemic therapies (including specific regimens). Exclusion covers HER2-positive disease, concurrent interventional trials, prior topoisomerase inhibitor-based ADCs, recent anticancer treatments (within 4 weeks/5 half-lives), and planned non-study therapies (excluding palliative radiotherapy).    Click to Show/Hide
Administration Dosage	IBI343: Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles.
Related Clinical Trial
NCT Number	NCT06238843	Phase Status	PHASE3
Clinical Description	A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Primary Endpoint	The primary endpoints include progression-free survival (PFS), measured as time from randomization to disease progression or death within approximately 20 months, and overall survival (OS), assessed as time from randomization to death within around 26 months.
Other Endpoint	Secondary endpoints consist of objective response rate (ORR), disease control rate (DCR), duration of response (DoR), time to response (TTR), and pharmacokinetic parameters like AUC, Cmax, Tmax, Ctrough, CL, and V. Additionally, immunogenicity assessments include incidence of anti-drug antibodies (ADA) and neutralizing antibodies (NAb), each evaluated within approximately 20 months.    Click to Show/Hide
Experiment 6 Reporting the Activity Date of This ADC					[5]
Patients Enrolled	Eligible participants must provide informed consent, have confirmed unresectable locally advanced/metastatic G/GEJ adenocarcinoma, CLDN18.2 positivity, ECOG PS 0-1, and adequate organ function. Exclusions cover active infections (HIV, HBV/HCV), uncontrolled comorbidities (cardiopulmonary, CNS metastases), recent major surgery/radiotherapy, immunosuppressive therapy, prior topoisomerase inhibitor ADCs, pregnancy, or conditions jeopardizing safety/study integrity. Specific thresholds apply for lab values (e.g., ANC ≥1.5×109/L, platelets ≥100×109/L) and disease stability (e.g., asymptomatic brain metastases ≤1.5 cm).    Click to Show/Hide
Administration Dosage	IBI343 Specifications: 100 mg/bottle Approval method: TBD Q3W intravenous infusion (IV) sintilimab Specifications: 100mg (10ml)/bottle Afghan way: 200 mg Q3W IV infusion
Related Clinical Trial
NCT Number	NCT06321913	Phase Status	PHASE2
Clinical Description	Phase II Study to Evaluate the Safety, Tolerability and Efficacy of IBI343 Combined With Sintilimab in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Primary Endpoint	The primary endpoints include Objective Response Rate (ORR) assessed per RECIST v1.1 and safety evaluations such as Adverse Events (AE), Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), Serious Adverse Events (SAE), and clinical monitoring parameters (laboratory exams, physical exams, vital signs), all tracked over 24 months.    Click to Show/Hide
Other Endpoint	Secondary efficacy measures consist of Progression-Free Survival (PFS), Duration of Response (DoR), Disease Control Rate (DCR), Time to Response (TTR), and Overall Survival (OS), each evaluated within a 24-month timeframe.

Experiment 1 Reporting the Activity Date of This ADC					[6]
Patients Enrolled	Inclusion: Part A/B-metastatic/unresectable solid tumors (ovarian/NSCLC/breast cancers, mesothelioma) refractory to prior therapy; Part C-BRCA-tested, platinum-resistant ovarian cancer (1-3 prior lines, FRalpha+ must have received mirvetuximab soravtansine); Part D-platinum-sensitive/refractory ovarian cancer (cohort-specific prior therapies); Part F-endometrial cancer (1-3 prior lines, post-PD-[L]1 inhibitor). Exclusions: ILD/pneumonitis, strong CYP3A inhibitors (dose escalation), prior topoisomerase-1 inhibitor ADCs.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT05579366	Phase Status	PHASE1|||PHASE2
Clinical Description	Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors
Primary Endpoint	In Parts A, B, and D, safety assessments include incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs) and dose-limiting toxicities (DLTs) evaluated through the end of treatment (up to ~1 year). DLTs are specifically analyzed at the end of Cycle 1 (21-day cycles). Parts C and F report objective response rate (ORR) via blinded independent central review (BICR) per RECIST v1.1.    Click to Show/Hide
Other Endpoint	Efficacy measures include best overall response (BOR), ORR, disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and duration of response (DOR). Pharmacokinetic parameters (Cmax, AUC, Tmax, Ctrough, t1/2) of Rina-S are assessed. Parts C and D evaluate CA-125 response using GCIG criteria, and Parts C and F assess adverse events (CTCAE v5.0).    Click to Show/Hide
Experiment 2 Reporting the Activity Date of This ADC					[7]
Patients Enrolled	Exclusions: prior topoisomerase-1 inhibitor ADCs; primary platinum-refractory disease (progression ≤91 days post-1st-line platinum); active malignancy within 3 years (exceptions: low-risk cancers); active CNS metastases (unless stable ≥4 weeks post-treatment); symptomatic GI obstruction/ascites requiring frequent paracentesis. Other protocol-specific criteria may apply.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT06619236	Phase Status	PHASE3
Clinical Description	A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
Primary Endpoint	The primary efficacy endpoints include progression-free survival (PFS), defined as time from randomization to first progression or death per RECIST v1.1, and overall survival (OS), measured from randomization to death from any cause. Secondary endpoints include objective response rate (ORR), duration of response (DOR), CA-125 response per GCIG criteria (≥50% reduction), PFS2 (time to second progression/death), and quality of life assessments via EORTC-QLQ-C30 (GHS/QoL score changes and time to deterioration [TTD]). Safety will be monitored through TEAEs, lab abnormalities, and ECG/QTc changes (Holter monitoring during Cycle 1).    Click to Show/Hide
Other Endpoint	Inclusion criteria: histologically confirmed high-grade serous/endometrioid ovarian, peritoneal, or fallopian tube cancer (regardless of FRalpha status) with 1-4 prior lines. Must have received platinum chemo, bevacizumab (if standard), and PARP inhibitors (if BRCA-mutated and eligible); prior mirvetuximab soravtansine required if FRalpha+ (unless contraindicated). Platinum-resistant disease defined as progression 91-183 days post-platinum (1st line) or ≤183 days (2nd-4th lines).    Click to Show/Hide
Experiment 3 Reporting the Activity Date of This ADC					[8]
Related Clinical Trial
NCT Number	NCT05579366	Phase Status	Phase 1/2
Clinical Description	Phase 1/2 study of PRO1184 in patients with locally advanced and/or metastatic solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[9]
Efficacy Data	stable disease (SD)	55%
Patients Enrolled	Eligible participants have histologically confirmed advanced/metastatic CRC refractory to standard therapies (MSI-H must have received checkpoint inhibitors if available), ECOG PS ≤1, and adequate organ function. Exclusions include other active malignancies (exceptions: non-melanoma skin/cervical cancers), unstable brain metastases, Grade >1 diarrhea/ileus, active IBD, significant cardiovascular events (MI/stroke within 6 months), or QTc >470 ms. Bowel obstruction/intestinal perforation history is also excluded.    Click to Show/Hide
Administration Dosage	This Phase 1 trial (NCT05464030) investigated the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity of M9140 as monotherapy (Q3W [Day 1 of 21-day cycles]; IV), At data cutoff (19 Jan 2024), 40 pts from the US, EU, and Japan were treated across 7 dose levels (DLs): 0.6 mg/kg, 1.2 mg/kg (n=3, each), 2.4 mg/kg (n=7), 2.6 mg/kg (n=4), 2.8 mg/ kg (n=12), 3.0 mg/kg (n 4), and 3.2 mg/kg (n=7, including 3 pts with primary G CSF prophylaxis).    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT05464030	Phase Status	PHASE1
Clinical Description	A Phase I, Multicenter, Open-Label First in Human Study of Anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants With Advanced Solid Tumors (PROCEADE-CRC-01)
Primary Endpoint	This study evaluates M9140 in participants with locally advanced/metastatic colorectal cancer (CRC), divided into multiple parts. Part 1 assesses dose-limiting toxicities (DLTs) and adverse events (AEs) to determine the recommended dose expansion (RDE) over 4 months. Parts 2A, 2B, 2C, and 2D further examine safety (AEs/DLTs), objective response (OR) per RECIST v1.1, and duration of response (DoR) over 8 months.    Click to Show/Hide
Other Endpoint	Pharmacokinetic (PK) analysis of M9140 plasma concentrations, anti-drug antibody (ADA) incidence/titers, ECG changes (QTc interval), and efficacy measures (OR, DoR, time to response, PFS) are assessed across all parts (1, 2A-2D). Part 2A includes overall survival (OS) and symptomatic AEs, while disease control is evaluated at Week 12.
Experiment 2 Reporting the Activity Date of This ADC					[9]
Efficacy Data	Partial Response (PR)	10%
Patients Enrolled	Eligible participants have histologically confirmed advanced/metastatic CRC refractory to standard therapies (MSI-H must have received checkpoint inhibitors if available), ECOG PS ≤1, and adequate organ function. Exclusions include other active malignancies (exceptions: non-melanoma skin/cervical cancers), unstable brain metastases, Grade >1 diarrhea/ileus, active IBD, significant cardiovascular events (MI/stroke within 6 months), or QTc >470 ms. Bowel obstruction/intestinal perforation history is also excluded.    Click to Show/Hide
Administration Dosage	This Phase 1 trial (NCT05464030) investigated the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity of M9140 as monotherapy (Q3W [Day 1 of 21-day cycles]; IV), At data cutoff (19 Jan 2024), 40 pts from the US, EU, and Japan were treated across 7 dose levels (DLs): 0.6 mg/kg, 1.2 mg/kg (n=3, each), 2.4 mg/kg (n=7), 2.6 mg/kg (n=4), 2.8 mg/ kg (n=12), 3.0 mg/kg (n 4), and 3.2 mg/kg (n=7, including 3 pts with primary G CSF prophylaxis).    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT05464030	Phase Status	PHASE1
Clinical Description	A Phase I, Multicenter, Open-Label First in Human Study of Anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants With Advanced Solid Tumors (PROCEADE-CRC-01)
Primary Endpoint	This study evaluates M9140 in participants with locally advanced/metastatic colorectal cancer (CRC), divided into multiple parts. Part 1 assesses dose-limiting toxicities (DLTs) and adverse events (AEs) to determine the recommended dose expansion (RDE) over 4 months. Parts 2A, 2B, 2C, and 2D further examine safety (AEs/DLTs), objective response (OR) per RECIST v1.1, and duration of response (DoR) over 8 months.    Click to Show/Hide
Other Endpoint	Pharmacokinetic (PK) analysis of M9140 plasma concentrations, anti-drug antibody (ADA) incidence/titers, ECG changes (QTc interval), and efficacy measures (OR, DoR, time to response, PFS) are assessed across all parts (1, 2A-2D). Part 2A includes overall survival (OS) and symptomatic AEs, while disease control is evaluated at Week 12.
Experiment 3 Reporting the Activity Date of This ADC					[14]
Patients Enrolled	Eligible participants must have histologically confirmed metastatic CRC refractory to standard therapies (fluoropyrimidine, irinotecan, platinum/EGFR/VEGF inhibitors) with ECOG PS ≤1 and adequate organ function. Key exclusions include active malignancies (exceptions: non-melanoma skin/cervical cancers), unstable brain metastases, uncontrolled diarrhea/ileus (Grade >1), or recent stroke (<6 months). MSI-H participants must have received checkpoint inhibitors unless contraindicated.    Click to Show/Hide
Administration Dosage	M9140 will be administered every 3 weeks until progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study. There will be 2 dose levels, if the low dose level is tolerated, then M9140 will be escalated to the high dose level.
Related Clinical Trial
NCT Number	NCT06806046	Phase Status	PHASE1
Clinical Description	A Phase 1, Open-label Study of AntiCEACAM5 AntibodyDrug Conjugate M9140 in Chinese Participants With Solid Tumors (PROCEADE-CRC-02)
Primary Endpoint	The study evaluates M9140 in participants with advanced/metastatic CRC, assessing dose-limiting toxicities (DLTs) during the first 21-day cycle and treatment-emergent adverse events (TEAEs) over 8 months. These primary safety endpoints will determine the tolerability profile of the investigational therapy.
Other Endpoint	Pharmacokinetic (PK) assessments will characterize plasma concentrations of M9140 across multiple cycles up to treatment discontinuation (≈20 months). Efficacy outcomes include objective response (OR), duration of response (DoR), and progression-free survival (PFS) per RECIST v1.1, measured from first treatment until disease progression/death (≈8 months).    Click to Show/Hide
Experiment 4 Reporting the Activity Date of This ADC					[15]
Patients Enrolled	Eligible participants must provide informed consent, have ECOG PS ≤1, adequate organ function, and ≥1 measurable lesion per RECIST v1.1. GC substudy requires HER2-negative advanced/metastatic adenocarcinoma with 1-2 prior lines including fluoropyrimidine/platinum (and ICI for MSI-H/PD-L1+), categorized by CEACAM5 expression. NSCLC substudy enrolls stage III/IV patients with 1-3 prior lines, analyzing CEACAM5 in EGFR-mutated tumors. PDAC substudy includes 1-2 prior lines (FOLFIRINOX/nal-IRI or gem/nab-paclitaxel) with CEACAM5high expression. Key exclusions include recent malignancies (exceptions apply), unstable brain metastases, Grade >1 diarrhea/ileus, inflammatory bowel disease, significant cardiac conditions (QTc>470ms), recent stroke (<6 months), and prior irinotecan use in GC/NSCLC substudies.    Click to Show/Hide
Administration Dosage	All participants will receive 2.8 milligram per kilogram (mg/kg) M9140 intravenously (i.v.) every 3 weeks (q3w) on Day 1 of consecutive 21-day cycles.
Related Clinical Trial
NCT Number	NCT06710132	Phase Status	PHASE1|||PHASE2
Clinical Description	PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)
Primary Endpoint	The substudies in gastric cancer (GC), non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC) will assess objective response (OR) per RECIST v1.1 from first treatment through final assessment at approximately 48 months, serving as a key efficacy parameter across all three cancer types.
Other Endpoint	Safety and efficacy outcomes for GC/NSCLC/PDAC substudies include adverse events (AEs), duration of response (DoR), disease control at Week 12, time to response, and progression-free survival (PFS) evaluated over 48 months. Pharmacokinetic analysis of M9140 plasma concentrations and anti-drug antibodies (ADA) will be monitored for approximately 12 months, with CEACAM5 expression specifically measured in the GC substudy on Day 1.    Click to Show/Hide

Experiment 1 Reporting the Activity Date of This ADC					[10]
Patients Enrolled	Eligible subjects must be ≥18yo with metastatic/advanced solid tumors (measurable per RECIST v1.1, ECOG 0-1) refractory to standard therapy, with adequate organ function (ALT/AST ≤3×ULN [≤5×ULN with liver mets], bilirubin ≤1.5×ULN, CrCl >50mL/min, ANC ≥1500/uL). Special populations: HIV+ (CD4≥350 cells/uL, VL<200 copies/mL), HBV (suppressed VL), HCV (curative treatment with undetectable VL). Part B requires NSCLC/SCLC histology. All subjects must provide pretreatment tumor biopsy (archival acceptable) and comply with contraception requirements (120 days post-treatment).    Click to Show/Hide
Administration Dosage	OBI-992 at dose level 1, 2, 3, 4, 6, 8, 10 mg/kg, Q3W
Related Clinical Trial
NCT Number	NCT06480240	Phase Status	PHASE1|||PHASE2
Clinical Description	A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-992 in Subjects With Advanced Solid Tumors
Primary Endpoint	Primary objectives include assessing OBI-992 safety/tolerability (AEs/SAEs/lab abnormalities per NCI CTCAE v5.0), determining MTD/RP2D, and evaluating preliminary efficacy (ORR, CBR, DOR, DCR, PFS per RECIST v1.1) over a study duration of up to 2 years and 2 months.
Other Endpoint	Secondary objectives involve characterizing OBI-992 immunogenicity (ADA incidence) and serum PK parameters (Cmax, AUC, T1/2, CL, Vdss) for both OBI-992 and active metabolite exatecan throughout the study period.

Experiment 1 Reporting the Activity Date of This ADC					[11]
Patients Enrolled	Key inclusion criteria: age ≥18; ECOG 0-1; measurable advanced solid tumors (RECIST 1.1); refractory to standard therapies; adequate organ function; willingness to provide tumor samples.
Related Clinical Trial
NCT Number	NCT06685068	Phase Status	PHASE1|||PHASE2
Clinical Description	A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Primary Endpoint	Primary endpoints include AE incidence (NCI-CTCAE v5.0) over 3 years 9 months and DLTs during first cycle (21 days) for GEN1286 safety evaluation.
Other Endpoint	Secondary endpoints comprise efficacy measures (ORR, DCR, PFS, DOR per RECIST 1.1) and PK parameters (AUC, Cmax, Tmax, t1/2, CL, Vz, Ctrough of antibody-conjugated exatecan components) over 2 years 9 months, plus ADA assessment.

Experiment 1 Reporting the Activity Date of This ADC					[12]
Patients Enrolled	Eligible patients (≥18 years, ECOG 0-1) had adequate organ function, measurable disease per RECIST v1.1, and resolved prior treatment toxicities (≤grade 1). Exclusions included recent anticancer therapy (<4 weeks/5 half-lives), uncontrolled brain metastases, or inadequate contraception. WOCBP required highly effective contraception during and post-treatment (5 half-lives + 6 months).    Click to Show/Hide
Administration Dosage	A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
Related Clinical Trial
NCT Number	NCT06657222	Phase Status	PHASE1|||PHASE2
Clinical Description	A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients with Advanced Solid Tumors (5-STAR 1-01)
Primary Endpoint	The MTD was defined as the highest dose where ≤1 of 3 patients experienced DLTs per NCI CTCAE v5.0, assessed from enrollment until 30 days post-treatment.
Other Endpoint	Safety outcomes included AE incidence, PK parameters (Cmax, Cmin, Tmax, AUC, T1/2), immunogenicity (anti-TUB-030 antibodies), and efficacy (ORR per RECIST 1.1), all evaluated until 30 days post-treatment.

Experiment 1 Reporting the Activity Date of This ADC					[13]
Patients Enrolled	Eligible patients (≥18 years, ECOG 0-1) had incurable solid tumors refractory to SoC, measurable disease, adequate organ function, and resolved prior toxicities (≤grade 1). Exclusions included topoisomerase-I refractory disease, active ILD/pneumonitis, uncontrolled comorbidities, recent live vaccines, or infections (HBV/HCV/HIV exceptions applied). Contraception was mandatory for FCBP.    Click to Show/Hide
Administration Dosage	A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
Related Clinical Trial
NCT Number	NCT06303505	Phase Status	PHASE1|||PHASE2
Clinical Description	A First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)
Primary Endpoint	The MTD was determined as the highest dose where ≤1 of 3 patients experienced DLTs per NCI CTCAE v5.0, evaluated from enrollment until 30 days post-treatment.
Other Endpoint	PK parameters (Cmax, Cmin, Tmax, AUC, T1/2) for TUB-040 components (ADC, mAb, payload) and immunogenicity (anti-TUB-040 antibodies) were assessed until 30 days post-treatment, alongside efficacy (ORR per RECIST 1.1).

Experiment 1 Reporting the Activity Date of This ADC					[16]
Patients Enrolled	Eligible patients aged 18-70 with histopathologically confirmed melanoma, non-small cell lung cancer (squamous), or head/neck squamous cell carcinoma must meet specific criteria including target protein expression, adequate venous access, and proper blood/liver/kidney function; exclusion factors cover active infections, prior CAR-T therapy, immunosuppressant use, severe systemic/autoimmune diseases, pregnancy, allergies, or prior organ transplants.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT05117138	Phase Status	PHASE1|||PHASE2
Clinical Description	Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors
Primary Endpoint	Primary endpoints include incidence of adverse events, overall response rate (ORR), and one-year recurrence rate, all evaluated over a 24-week timeframe.
Other Endpoint	Secondary endpoints comprise progression-free survival (PFS) and relapse-free survival (RFS), also measured within a 24-week period.
Experiment 2 Reporting the Activity Date of This ADC					[17]
Patients Enrolled	Eligibility requires signed ICF, advanced solid tumors, progression after prior therapy, measurable lesions, ECOG 0-1, ≥3 month life expectancy, adequate organ function, and contraceptive use. Exclusions include prior target therapy, CNS metastases, severe skin disorders, unresolved toxicities (>Grade 1), recent treatments/surgeries, cardiac issues, thromboembolic events, active infections, or recent live vaccines.    Click to Show/Hide
Administration Dosage	Administered intravenously
Related Clinical Trial
NCT Number	NCT06209580	Phase Status	PHASE1|||PHASE2
Clinical Description	Phase I/II Study of AMT-253 in Patients With Unresectable or Metastatic Malignant Melanoma and Other Advanced Solid Tumors
Primary Endpoint	The study assesses DLTs (21 days post-dose), AEs/SAEs (24 months) including type, incidence and severity, and ORR per RECIST 1.1.
Other Endpoint	Pharmacokinetic metrics over 24 months include Cmax, Tmax, AUC, t1/2 of ADC components, and ADA quantification.
Experiment 3 Reporting the Activity Date of This ADC					[18]
Patients Enrolled	Eligible patients must be ≥18 years, with progressive disease after systemic therapy, measurable lesions per RECIST v1.1, ECOG 0-1, adequate organ function, and life expectancy ≥3 months. Key exclusions include CNS metastasis, active infections, significant cardiac/autoimmune diseases, recent major surgery/radiotherapy, unresolved toxicities >Grade 1, pregnancy, or prior malignancies within 5 years (unless inclusion-related). Contraception and tumor tissue availability are required.    Click to Show/Hide
Administration Dosage	Administered intravenously
Related Clinical Trial
NCT Number	NCT05906862	Phase Status	PHASE1
Clinical Description	First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors
Primary Endpoint	The study focuses on determining the Recommended Phase 2 Dose (RP2D) and Maximum Tolerated Dose (MTD) based on dose-limiting toxicities (DLTs) and other data over 24 months. Safety and tolerability will be assessed using Common Terminology Criteria for Adverse Events v5.0 to evaluate adverse event types, incidence, and severity.
Other Endpoint	Key efficacy endpoints include Overall Response Rate (ORR) and Disease Control Rate (DCR) per RECIST v1.1, along with Progression-free Survival (PFS). Pharmacokinetic profiling will assess Cmax, AUC, terminal half-life (t1/2), and Tmax of AMT-253, while immunogenicity will be evaluated via anti-drug antibody (ADA) concentrations, all measured over 24 months.    Click to Show/Hide

Experiment 1 Reporting the Activity Date of This ADC					[19]
Patients Enrolled	Eligible patients must have confirmed metastatic/unresectable RCC, NPC, or NHL (stage III/IV), be refractory to prior therapies, have ECOG 0-1, and measurable disease. Exclusions include previous anti-CD70 therapy, active CNS metastases (unless treated/stable), uncontrolled infections, HBV/HCV/HIV positivity, or recent strong CYP3A inhibitor use (dose escalation only).    Click to Show/Hide
Administration Dosage	PRO1160 monotherapy in escalating doses in Part A and at the recommended phase 2 dose in Part B
Related Clinical Trial
NCT Number	NCT05721222	Phase Status	PHASE1|||PHASE2
Clinical Description	Phase 1/2 Study of PRO1160 in Patients With Renal Cell Carcinoma (RCC), Nasopharyngeal Carcinoma (NPC), or Non-Hodgkin Lymphoma (NHL)
Primary Endpoint	Safety will be evaluated by assessing treatment-emergent adverse events (frequency, severity, and seriousness) and dose-limiting toxicities throughout the treatment period up to approximately 1 year.
Other Endpoint	Efficacy measurements include objective response rate, disease control rate (assessed by RECIST v1.1 for solid tumors or Lugano 2014 for NHL), progression-free survival (analyzed up to 18 months), and duration of response (tracked until disease progression/withdrawal). Pharmacokinetic analysis will determine PRO1160's peak plasma concentration (Cmax).    Click to Show/Hide
Experiment 2 Reporting the Activity Date of This ADC					[20]
Related Clinical Trial
NCT Number	NCT05721222	Phase Status	Phase 1/2
Clinical Description	Phase 1/2 study of PRO1160 in patients with renal cell carcinoma (RCC), nasopharyngeal carcinoma (NPC), or non-Hodgkin lymphoma (NHL).

Experiment 1 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Objective Response Rate (ORR)	41.70%
Patients Enrolled	Eligible participants aged 18-75 with advanced solid tumors (platinum-resistant ovarian cancer, NSCLC, etc.) must have measurable lesions (RECIST 1.1), ECOG 0-1, adequate organ function, and FRalpha-positive tumors (for expansion cohorts). Exclusions include recent systemic therapy, unresolved toxicities, active infections (HIV/HBV/HCV), uncontrolled cardiovascular disease, severe bleeding/thrombosis history, CNS metastases requiring treatment, pregnancy, or conditions compromising compliance.    Click to Show/Hide
Administration Dosage	Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30~120 minutes.
Related Clinical Trial
NCT Number	NCT05378737	Phase Status	PHASE1
Clinical Description	A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of BAT8006 for Injection in Patients With Advanced Solid Tumors
Primary Endpoint	The study evaluates dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of the investigational drug, with DLT defined as grade ≥3 toxicities within 21 days of first administration, and MTD identified as the highest dose level where ≤1/6 subjects experience DLT.
Other Endpoint	Pharmacokinetic (PK) analysis focuses on Cmax during the first six 21-day treatment cycles, assessing drug exposure and concentration-time profiles.
Experiment 2 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Disease control rate (DCR)	86.10%
Patients Enrolled	Eligible participants aged 18-75 with advanced solid tumors (platinum-resistant ovarian cancer, NSCLC, etc.) must have measurable lesions (RECIST 1.1), ECOG 0-1, adequate organ function, and FRalpha-positive tumors (for expansion cohorts). Exclusions include recent systemic therapy, unresolved toxicities, active infections (HIV/HBV/HCV), uncontrolled cardiovascular disease, severe bleeding/thrombosis history, CNS metastases requiring treatment, pregnancy, or conditions compromising compliance.    Click to Show/Hide
Administration Dosage	Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30~120 minutes.
Related Clinical Trial
NCT Number	NCT05378737	Phase Status	PHASE1
Clinical Description	A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of BAT8006 for Injection in Patients With Advanced Solid Tumors
Primary Endpoint	The study evaluates dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of the investigational drug, with DLT defined as grade ≥3 toxicities within 21 days of first administration, and MTD identified as the highest dose level where ≤1/6 subjects experience DLT.
Other Endpoint	Pharmacokinetic (PK) analysis focuses on Cmax during the first six 21-day treatment cycles, assessing drug exposure and concentration-time profiles.
Experiment 3 Reporting the Activity Date of This ADC					[31]
Patients Enrolled	Eligible participants must be ≥18 years old with platinum-resistant ovarian, peritoneal, or fallopian tube cancer, measurable lesions per RECIST v1.1, and adequate organ function. Exclusions include pregnancy, recent surgery or transplants, active infections, HIV/hepatitis B/C, prior malignancies, allergies to BAT8006, live vaccines within 4 weeks, or conditions undermining compliance.    Click to Show/Hide
Administration Dosage	Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30~60 minutes.
Related Clinical Trial
NCT Number	NCT06545617	Phase Status	PHASE1|||PHASE2
Clinical Description	A Phase 1b/2, Multicenter, Open-Label Study of BAT8006, an Anti- FRalpha Antibody Drug Conjugate (ADC) for Platinum-resistant Ovarian Cancer Subjects
Primary Endpoint	This study aims to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of BAT8006, assessing dose-limiting toxicities (DLTs) and overall tolerability. Safety evaluations include monitoring adverse events (AEs), physical examinations, ECOG score changes, vital signs, laboratory results, ECG, Echo/MUGA, and ophthalmologic findings, tracked from informed consent through 30 days post-treatment, up to 27 months.    Click to Show/Hide
Other Endpoint	Immunogenicity of BAT8006 will be evaluated by measuring ADA/NAb levels, while efficacy endpoints include objective response rate (ORR), duration of response (DOR), best percentage change in tumor size, and progression-free survival (PFS). Pharmacokinetics (PK) parameters such as Cmax, Tmax, AUC, and terminal half-life (t½) will be analyzed across multiple cycles.    Click to Show/Hide
Experiment 4 Reporting the Activity Date of This ADC					[36]
Related Clinical Trial
NCT Number	NCT05378737	Phase Status	Phase 1
Clinical Description	A multicenter, open phase 1 clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of BAT8006 for injection in patients with advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[22]
Patients Enrolled	Eligible patients are adults (≥18 years) with histologically confirmed advanced/metastatic solid tumors refractory to standard therapy, measurable lesions per RECIST 1.1, ECOG PS 0-1, adequate organ function, and compliance with contraception. Exclusions involve recent experimental/tumor therapy (within 4 weeks), prior Trop2-targeted treatment, severe topoisomerase I inhibitor toxicity, major surgery (within 4 weeks), or organ transplantation history.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT05620017	Phase Status	PHASE1
Clinical Description	A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Initial Efficacy of BAT8008 for Injection in Patients With Advanced Solid Tumor
Primary Endpoint	The primary endpoints include dose-limiting toxicity (DLT), defined as grade ≥3 toxicity related to the investigational product within the first 21-day cycle, and maximum tolerated dose (MTD), determined as the highest dose with ≤1/6 subjects experiencing DLT during evaluation.
Other Endpoint	Pharmacokinetic analysis includes AUC (0-inf) after cycle 6, measuring the area under the concentration-time curve from time 0 extrapolated to infinity, assessed 91 days post-first dose.
Experiment 2 Reporting the Activity Date of This ADC					[23]
Patients Enrolled	Eligible patients are adults (≥18) with advanced/metastatic epithelial solid tumors (e.g., triple-negative breast cancer, NSCLC) refractory to standard therapy, measurable lesions (RECIST 1.1), ECOG PS 0-1, and adequate organ function. Key exclusions: recent experimental/anti-tumor therapy (4 weeks), prior Trop2-ADC/toisomerase I inhibitor toxicity, uncontrolled CNS metastases, active infections (HIV/HBV/HCV), severe cardiovascular disease, or immunosuppressive therapy within 14 days.    Click to Show/Hide
Administration Dosage	BAT1308 injection: 25 mg/mL concentrate for solution for infusion.200 mg on Day 1 of each 14-day cycle BAT8008 injection: 20 mg/mL concentrate for solution for infusion.Climbing group A: 2.1mg/kg on Day 1 of each 14-day cycle,and Climbing group B: 2.4mg/kg on Day 1 of each 14-day cycle
Related Clinical Trial
NCT Number	NCT06341114	Phase Status	PHASE1|||PHASE2
Clinical Description	A Multicenter, Open-label Phase Ib-II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors
Primary Endpoint	Primary outcomes include dose-limiting toxicity (DLT) assessed within the first 21-day cycle, vital signs, physical exams, adverse events (AEs) per CTCAE v5.0, clinical lab abnormalities, and efficacy metrics (ORR, DOR, DCR, PFS, and OS) evaluated over a 1-year period via RECIST 1.1 criteria.
Other Endpoint	Pharmacokinetic parameters (Tmax, CL, t½, Cmax, ADA, and Nab levels) are assessed at multiple timepoints across cycles (C1D1-C4D1, then every 4 cycles up to 26 cycles, each lasting 2 weeks).

Experiment 1 Reporting the Activity Date of This ADC					[24]
Patients Enrolled	Key inclusion: Nectin-4-expressing unresectable/metastatic solid tumors, prior systemic therapy, measurable disease (RECIST 1.1), adequate organ function. Key exclusion: brain metastases, active/latent infections, ILD, recent thromboembolic/cardiovascular events, recent surgery or immunosuppressive therapy, CYP3A4 modifiers, or live vaccines within specified periods.    Click to Show/Hide
Administration Dosage	Part 1 (dose escalation) and Part 2 (dose optimization)
Related Clinical Trial
NCT Number	NCT06781983	Phase Status	PHASE1
Clinical Description	A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors
Primary Endpoint	The study evaluates safety and tolerability, monitoring adverse events (AEs, SAEs, TEAEs) and dose-limiting toxicities (DLTs) over 24 months from first dose through treatment and follow-up.
Other Endpoint	Pharmacokinetic analysis includes assessing Cmax, AUC, and ADA incidence against IPH4502, alongside preliminary antitumor activity metrics (ORR, DoR, PFS) over 24 months from informed consent through treatment and follow-up.

Experiment 1 Reporting the Activity Date of This ADC					[25]
Patients Enrolled	Eligible participants include those with specific solid tumors like ovarian, endometrial, cervical, NSCLC, TNBC, pancreatic, or colorectal cancer across various cohorts. Exclusion criteria involve uncontrolled CNS metastases, carcinomatous meningitis, active infections, corneal issues, unresolved toxicities, cardiovascular disease, prolonged QTcF (≥470 ms), pneumonitis history, or pregnancy/breastfeeding.    Click to Show/Hide
Administration Dosage	The study has 2 phases: phase 1a dose escalation/dose optimization and phase 1b dose expansion. Dose escalation follows the mTPI-2 method. Pts are allowed to backfill to previously cleared dose levels that have demonstrated therapeutically relevant exposures or shown direct evidence of clinical activity. LY4170156 is administered intravenously Q3W; DLT evaluation period is 21 days. In dose expansion, pts with select tumor types are enrolled into 4 cohorts: PROC with high (cohort B1) and moderate/low (cohort B2) FRalpha expression and select advanced/metastatic non-ovarian cancer with high (cohort C1) and moderate/low FRalpha expression (cohort C2).    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT06400472	Phase Status	PHASE1
Clinical Description	A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor alpha-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
Primary Endpoint	Phase 1a focuses on determining the recommended phase 2 dose (RP2D) of LY4170156, either as monotherapy or in combination with bevacizumab or carboplatin, measured by dose-limiting toxicities (DLTs) over a 21-day cycle. Phase 1b evaluates the antitumor activity of LY4170156 monotherapy, with overall response rate (ORR) assessed via RECIST 1.1 over approximately 48 months.    Click to Show/Hide
Other Endpoint	This section characterizes the pharmacokinetics (PK) of LY4170156 through metrics like minimum plasma concentration (Cmin) and area under the curve (AUC) over 84 days. Additionally, it evaluates preliminary antitumor activity, including ORR, duration of response (DOR), time to response (TTR), progression-free survival (PFS), and disease control rate (DCR), all assessed via RECIST 1.1, with or without bevacizumab/carboplatin, over approximately 48 months.    Click to Show/Hide

Experiment 1 Reporting the Activity Date of This ADC					[26]
Patients Enrolled	Eligible patients (≥18 years) with advanced solid tumors after prior therapy provide informed consent, have measurable disease (RECIST 1.1), ECOG 0-1, and adequate organ function (ANC ≥1.5x109/L, platelets ≥100x109/L, hemoglobin ≥9.0g/dL, CrCl ≥45mL/min, LVEF ≥50%). Exclusion criteria: prior TOP1-ADC treatment, active brain metastases, unresolved Grade >1 toxicities, recent systemic therapy/radiation/surgery, significant cardiac/liver disease, infections (HIV/HBV/HCV under control allowed), pregnancy, or concurrent clinical trials.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT06234423	Phase Status	PHASE1
Clinical Description	A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-directed Antibody-Drug Conjugate, in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Primary Endpoint	Phase 1a and 1b evaluate the safety and tolerability of CUSP06 over 36 months, recording adverse events (AEs), serious adverse events (SAEs), dose interruptions, and reductions per NCI CTCAE v5.0, while Phase 1a determines the recommended dose for expansion (RDE) within 15 months. In Phase 1b, preliminary efficacy is assessed via RECIST 1.1, measuring the overall response rate (ORR) over 16 months, defined as confirmed partial (PR) or complete responses (CR).    Click to Show/Hide
Other Endpoint	CUSP06's pharmacokinetics (PK) are evaluated, including maximum concentration (Cmax), time to Cmax (Tmax), area under the curve (AUC), and terminal half-life (t1/2) over 36 months. Efficacy metrics include RECIST 1.1-defined ORR (18 months), disease control rate (DCR), clinical benefit rate (CBR), duration of response (DoR), time to progression (TTP), progression-free survival (PFS), overall survival (OS), and PRROC patients' CA-125 reduction ≥50% (36 months). Immunogenicity is also assessed via antidrug antibodies (ADAs).    Click to Show/Hide

Experiment 1 Reporting the Activity Date of This ADC					[27]
Patients Enrolled	Eligible patients have specified advanced solid tumors (urothelial, TNBC, NSCLC, etc.) with disease progression after prior therapies (requirements vary by cohort). Key requirements include ECOG 0-1, measurable disease (except Cohort A1), and available tumor tissue. Exclusion criteria include CNS metastases, uncontrolled comorbidities (hypercalcemia, diabetes), corneal disease, recent thromboembolic events, QTcF ≥470ms, or active infections.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT06238479	Phase Status	PHASE1
Clinical Description	A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Primary Endpoint	The Phase 1a primary objective is to establish LY4101174's recommended dose based on dose-limiting toxicities (DLTs) observed within the first two 28-day cycles. Phase 1b evaluates antitumor activity through overall response rate (ORR) as per RECIST 1.1 criteria over approximately 4 years.
Other Endpoint	Pharmacokinetic analysis assesses minimum plasma concentration (Cmin) and area under curve (AUC) during initial treatment cycles (56 days). Antitumor evaluation includes multiple efficacy measures: ORR, duration of response (DOR), time to response (TTR), progression-free survival (PFS), disease control rate (DCR) and overall survival (OS) - all assessed per RECIST 1.1 over ~4 years.    Click to Show/Hide

Experiment 1 Reporting the Activity Date of This ADC					[28]
Patients Enrolled	Eligible patients (18-75 years, ECOG 0-1) must have advanced solid tumors failing standard therapy, measurable lesions per RECIST 1.1, and adequate organ function. Key exclusions include prior Nectin-4 treatment, uncontrolled cardiovascular disease (NYHA≥2, QTc>450/470ms), active HIV/HBV/HCV/syphilis, untreated tuberculosis, recent major surgery/thromboembolism, or live vaccinations within 4 weeks. COVID-19 vaccination requires ≥14-day separation from treatment initiation.    Click to Show/Hide
Administration Dosage	Subjects with advance solid tumor received BAT8007 on day 1 of a 21-day cycle until subject intolerance or disease progression.
Related Clinical Trial
NCT Number	NCT05879627	Phase Status	PHASE1
Clinical Description	A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors
Primary Endpoint	The study will assess dose-limiting toxicities (DLTs) within 21 days post-initial BAT8007 dose using NCI CTCAE v5.0, alongside continuous adverse event (AE) monitoring from first dose to 28 days post-treatment or until new antitumor therapy begins.
Other Endpoint	Immunogenicity (ADA levels) and neutralizing antibodies (NAb) will be tracked through Cycle 3 (14-day cycles), alongside pharmacokinetic analyses including Cmax, Tmax, T1/2, and systemic clearance.

Experiment 1 Reporting the Activity Date of This ADC					[29]
Patients Enrolled	Eligible patients must be ≥18 years with histologically confirmed unresectable advanced solid tumors, prior systemic therapy failure, ECOG 0-1, adequate organ function, and at least one measurable lesion. Key exclusions include CNS metastasis, unresolved toxicities from prior therapy, active infections, recent major surgery or radiotherapy, significant cardiac disease, or concurrent investigational trial participation. Pregnancy, substance abuse, and uncontrolled medical/psychiatric conditions also disqualify candidates.    Click to Show/Hide
Administration Dosage	Administered AMT-562 for injection intravenously
Related Clinical Trial
NCT Number	NCT06199908	Phase Status	PHASE1
Clinical Description	First-in-Human, Phase 1 Study of AMT-562 in Patients With Advanced Solid Tumors
Primary Endpoint	The study assesses safety endpoints including Dose Limiting Toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs), evaluated for type, incidence, and severity over a 24-month timeframe.
Other Endpoint	Pharmacokinetic parameters such as Cmax, Tmax, AUC, t1/2, and Anti-Drug Antibodies (ADAs) are measured, alongside efficacy outcomes including ORR, DCR, PFS, TTR, and DOR, all assessed per RECIST v1.1 over 24 months.

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 71.80%	Low HER3 expression (HER3+)
Method Description	AMT-562 (10 mg/kg, day 1) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
In Vivo Model	Pancreatic cancer PDX model (PDX: PDX-200930)
Experiment 2 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Low HER3 expression (HER3+)
Method Description	AMT-562 (10 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
In Vivo Model	Pancreatic cancer PDX model (PDX: PDX-361319)
Experiment 3 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Low HER3 expression (HER3+)
Method Description	AMT-562 (10 m ug/kg, every seven days x3) induces efficient tumor cell killing in cell line-derived models of Pancreatic cancer cell with HER3 expression with high expression.
In Vivo Model	Squamous cell carcinoma PDX model (PDX: PDX-361318)

Experiment 1 Reporting the Activity Date of This ADC					[30]
Patients Enrolled	Eligible participants must be 18-75 years old with advanced/metastatic solid tumors refractory to standard therapy, adequate organ function, and measurable disease per RECIST v1.1, while exclusions involve pregnancy, active CNS metastases, recent major surgery, severe infections, HIV/hepatitis B/C, or prior Grade 3-4 antibody therapy reactions, ensuring patient safety and protocol adherence.    Click to Show/Hide
Administration Dosage	BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30~120 minutes.
Related Clinical Trial
NCT Number	NCT05405621	Phase Status	PHASE1
Clinical Description	A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009 in Patients With Advanced Solid Tumours
Primary Endpoint	The primary endpoint assesses dose-limiting toxicity (DLT) occurring within 21 days post-initial BAT8009 administration, defining toxicity parameters during the observation period to evaluate safety tolerability.
Other Endpoint	Secondary endpoints include pharmacokinetic measures like Cmax (maximum serum concentration) and AUC0-inf/AUC0-λ over 126 days, alongside immunogenicity monitoring for anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) to characterize drug exposure and immune response profiles.
Experiment 2 Reporting the Activity Date of This ADC					[35]
Related Clinical Trial
NCT Number	NCT05405621	Phase Status	Phase 1
Clinical Description	A phase 1, multi-center, open-label study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of BAT8009 in patients with advanced solid tumours.

Experiment 1 Reporting the Activity Date of This ADC					[32]
Patients Enrolled	Eligibility requires ECOG 0-1, HER2-expressing tumors (IHC3+/2+), measurable lesions (RECIST 1.1), and adequate organ function. Key exclusions include prior HER2-targeted therapy with grade ≥3 toxicity, uncontrolled CNS metastases, major surgery <28 days, active HBV/HCV/syphilis infection, NYHA II-IV heart failure, interstitial lung disease, or pregnancy. Recent anti-tumor therapies (<28 days) or radiopharmaceuticals (<8 weeks) are prohibited, with investigator discretion for other compromising conditions.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT05848466	Phase Status	PHASE1
Clinical Description	A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BAT8010 for Injection in Patients With Advanced or Metastatic Solid Tumors
Primary Endpoint	The study defines dose-limiting toxicity (DLT) as grade 5 toxicity, grade 4 hepatotoxicity (ALT/AST >5xULN with bilirubin elevation), prolonged grade 4 hematologic toxicities (>7 days), febrile neutropenia, or any grade ≥3 non-hematologic toxicity. The maximum tolerated dose (MTD) is identified as the highest dose where DLTs occur in ≤1/6 subjects within the 3-week evaluation period.    Click to Show/Hide
Other Endpoint	Pharmacokinetic analysis monitors Cmax per 3-week cycle up to 18 weeks, while immunogenicity tracks ADA/NAb levels throughout treatment (cycles 1-18 weekly, then every 4 cycles up to 1 year). Efficacy endpoints include ORR (CR+PR rates at 18 weeks and overall), DoR (response duration until progression/death), DCR (CR+PR+SD), PFS (time to progression/death), and OS (time to death from any cause) over a 2-year average follow-up.    Click to Show/Hide
Experiment 2 Reporting the Activity Date of This ADC					[33]
Patients Enrolled	Eligible patients must be ≥18 years with ECOG 0-1, HER2-positive tumors (IHC3+/2+ ± FISH), measurable lesions (RECIST 1.1), and adequate organ function. Key exclusions: prior HER2-targeted therapy with grade ≥3 toxicity/LVEF <50%, uncontrolled CNS metastases, major surgery (<28 days), active infections (HBV/HCV/syphilis), NYHA II-IV cardiac dysfunction, or interstitial lung disease. Prohibited concurrent therapies include recent anti-tumor treatments (<28 days), radiopharmaceuticals (<8 weeks), and pregnancy/lactation, with investigator discretion for other high-risk conditions affecting compliance.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT06376136	Phase Status	PHASE1|||PHASE2
Clinical Description	An Evaluation of BAT 8010 for Injection in Combination With BAT 1006 in Locally Advanced or Metastatic Entities Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of the Tumor in Patients Multicenter, Open Phase Ib/IIa Clinical Study
Primary Endpoint	Safety assessments include monitoring dose-limiting toxicities (DLT) during the first 21-day cycle, tracking abnormal vital signs (including blood pressure, pulse, temperature), physical examinations, adverse events (AEs) from first dose until 28 days post-treatment or new therapy initiation, and clinical lab abnormalities (hematology, biochemistry) over 1 year, alongside efficacy metrics like duration of response (DOR) and disease control rate (DCR) tracking tumor response stability and shrinkage.    Click to Show/Hide
Other Endpoint	Pharmacokinetic profiling evaluates Cmax, Tmax, clearance rate (CL), and half-life (T1/2) at multiple timepoints across cycles 1-6 and end-of-treatment (17 cycles of 2 weeks each). Immunogenicity testing measures anti-drug antibodies (ADA) and neutralizing antibodies (NAb) at cycle starts (cycles 1-3, 5-6) and EOT to assess drug exposure and immune response patterns over the treatment trajectory.    Click to Show/Hide

Experiment 1 Reporting the Activity Date of This ADC					[34]
Patients Enrolled	Eligible patients must have unresectable advanced solid tumors (e.g., colorectal, gastric, or pancreatic cancers), ECOG 0-1, and adequate organ function. Key exclusions include prior ADC/targeted therapy, CNS metastasis, active infections, severe cardiac/respiratory conditions, recent major surgery/radiation, pregnancy, or concurrent investigational treatment.    Click to Show/Hide
Administration Dosage	Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).
Related Clinical Trial
NCT Number	NCT06400485	Phase Status	EARLY_PHASE1
Clinical Description	First-in-Human, Phase 1 Study of AMT-676 in Patients With Advanced Solid Tumors
Primary Endpoint	The study focuses on determining the Recommended Phase 2 Dose (RP2D) and Maximum Tolerated Dose (MTD) based on dose-limiting toxicities (DLTs) and safety profiles, with assessments within 30 days post-dosing. Adverse events will also be evaluated using CTCAE v5.0 for severity and incidence.
Other Endpoint	Pharmacokinetic parameters such as Cmax, Tmax, AUC, and t1/2 of AMT-676 will be measured within 30 days post-dosing. Immunogenicity will be assessed via anti-drug antibody (ADA) levels, while efficacy endpoints include ORR (CR/PR), DCR (CR/PR/SD), and PFS per RECIST v1.1.

Experiment 1 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 59%	Negative HER2 expression (HER2 -)
Method Description	T moiety (We conducted a four-week (day 1, 8, 15, 22, and 29) intermittent intravenous dose toxicity study of exatecan mesylate in rats (six animals/group) with a four-week recovery period (three of the six animals).
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 20%
Method Description	ADC4 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model at 10 mg/kg single doses and was found to reduce the rate of tumor growth compared to vehicle
In Vivo Model	MDA-MB-231 Xenograft Model
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%
Method Description	ADC4 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 6 mg/kg on day 1, dayv8 and day 15. time lasted 57 days.
In Vivo Model	MDA-MB-231 Xenograft Model
Experiment 3 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 80%
Method Description	ADC4 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 10 mg/kg on day 1, dayv8 and day 15. time lasted 57 days.
In Vivo Model	MDA-MB-231 Xenograft Model

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 30%
Method Description	ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model at 6 mg/kg single doses and was found to reduce the rate of tumor growth compared to vehicle
In Vivo Model	MDA-MB-231 Xenograft Model
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 60%
Method Description	ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model at 10 mg/kg single doses and was found to reduce the rate of tumor growth compared to vehicle
In Vivo Model	MDA-MB-231 Xenograft Model
Experiment 3 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 60%
Method Description	ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 10 mg/kg was found to reduce the rate of tumor growth compared to vehicle
In Vivo Model	MDA-MB-231 Xenograft Model
Experiment 4 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 80%
Method Description	ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 6 mg/kg was found to reduce the rate of tumor growth compared to vehicle
In Vivo Model	MDA-MB-231 Xenograft Model
Experiment 5 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 90%
Method Description	ADC3 was examined in a MDA-MB-231 (Triple Negative Breast Cancer), target antigen + model after three doses at 3 mg/kg was found to reduce the rate of tumor growth compared to vehicle
In Vivo Model	MDA-MB-231 Xenograft Model

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CALU-6 expression (CALU-6+++/++)
Method Description	ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 3 mg/kg.
In Vivo Model	NSCLC CALU-6 (lung cancer) model
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CALU-6 expression (CALU-6+++/++)
Method Description	ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 6 mg/kg.
In Vivo Model	NSCLC CALU-6 (lung cancer) model
Experiment 3 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CALU-6 expression (CALU-6+++/++)
Method Description	ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 10 mg/kg.
In Vivo Model	NSCLC CALU-6 (lung cancer) model
Experiment 4 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%
Method Description	ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 3 mg/kg.
In Vivo Model	MDA-MB-231 (TNBC) model
Experiment 5 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%
Method Description	ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 6 mg/kg.
In Vivo Model	MDA-MB-231 (TNBC) model
Experiment 6 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%
Method Description	ADC3 (DAR of 8) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 10 mg/kg.
In Vivo Model	MDA-MB-231 (TNBC) model

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth lnhibition value (TGl)	101%
Method Description	Animal experiments were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee of Seoul National University. A heterogeneous tumor model was established by subcutaneously injecting a mixture of 1 × 107 JIMT-1 cells and 2.5 × 106 MDA-MB-231 cells in 100 uL PBS into the dorsal flank of 6-week-old female NU/J mice (OrientBio) [29]. This 4:1 co-implantation reflects the diverse composition often observed in advanced HER2-positive breast cancer while ensuring enough HER2-negative cells to model intratumor heterogeneity [29]. When tumors reached approximately 150 mm3, mice were randomly assigned to different experimental groups and received intravenous injections of PBS (Control), IgG DEVD ADC, HER2 DEVD ADC, or T-Dxd (trastuzumab deruxtecan) at a dose of 5 mg/kg weekly for four weeks. This 5 mg/kg dose aligns with the range commonly used in prior preclinical trastuzumab-based ADC evaluations [7,12] and follows recent analysis [30] suggesting that efficacy in mice is most meaningful when the mg/kg dose approximates the maximum tolerated dose seen in human trials. Tumor volumes and body weights were measured every three days. Tumor volume was calculated using the ellipsoidal formula: volume = (length × width2)/2. The tumor growth inhibition (%TGI) was calculated using the formula: %TGI = [1 - (Tt/T0)/ (Ct/C0)]/[1- (C0/Ct)] × 100, where Tt and Ct are the mean tumor volumes of the treatment and control groups at the endpoint, and T0 and C0 are the initial tumor volumes. Mice were euthanized when tumors exceeded 1000 mm3 or if severe distress was observed. Tumors were harvested for histological analysis.    Click to Show/Hide
In Vivo Model	HER2-positive JIMT-1 cells and HER2-negative MDA-MB-231 cells in a 4:1 ratio Immunodeficient mice model

Experiment 1 Reporting the Activity Date of This ADC					[41]
Efficacy Data	Half Maximal inhibitory Concentration (lC54)	0.049 nM	Positive HER2 expression (HER2+++/++)
Method Description	Chemiluminescence staining (Luminescent Cell Viability Assay) was carried out, and IC9owas calculated after reading the fluorescence data.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[41]
Efficacy Data	Half Maximal inhibitory Concentration (lC53)	18.5 nM	Positive HER2 expression (HER2+++/++)
Method Description	Chemiluminescence staining (Luminescent Cell Viability Assay) was carried out, and IC8owas calculated after reading the fluorescence data.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[41]
Efficacy Data	Half Maximal inhibitory Concentration (lC52)	0.187 nM	Positive HER2 expression (HER2+++/++)
Method Description	Chemiluminescence staining (Luminescent Cell Viability Assay) was carried out, and IC7owas calculated after reading the fluorescence data.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.07&#1770.01 nM	High CEACAM5 expression (CEACAM5 +++)
Method Description	Human cancer cell lines were obtained from the American Type Culture Collection (CEA5-positive: SK-CO-1, MKN-45, LS174T; CEA5-negative MDA-MB-231) and maintained according to standard culture conditions (SK-CO-1, MKN-45: 37 °C, 5% CO2, 95% humidity; LS174T, MDA-MB-231: 37 °C, 10% CO2, 95% humidity). SK-CO-1 cells were cultured in Minimum Essential Medium Eagle (Sigma-Aldrich, FG0325) including l-alanylglutamine supplemented with 10% fetal bovine serum (FBS) and 1 mM sodium pyruvate. LS174T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich, FG0435) including l-alanyl-glutamine supplemented with 10% FBS, 1 mM sodium pyruvate, and 1% (v/v) nonessential amino acid 100× mix (Sigma-Aldrich, M7145). MDA-MBA-231 cells were cultured in DMEM including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. MKN-45 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 (Sigma-Aldrich, FG1215) medium including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. For subculturing, adherent cells were detached by the addition of TrypLE Express (1×) (Gibco, 12604-013), diluted with fresh medium, and transferred into a new culturing flask. For the evaluation of exatecan and exatecan conjugates, 90 uL of viable cell (vc) suspension was seeded into 96-well plates (SK-CO-1 2,500 vc/well, MKN-45 500 vc/well, LS174T 2,500 vc/well, MDA-MB-231 1,500 vc/well) followed by incubation (37 °C, 5 or 10% CO2) in a humid chamber overnight. Test compounds were formulated at a 10-fold starting concentration, prepared in serial dilution (1:4), and 10 uL was added to cells for each dilution in triplicates. The cell viability was determined after 6 days using the CellTiter-Glo reagent (Promega, G7573) according to the manufacturer's instructions. Luminescence values were measured by using a Varioskan plate reader (Thermo Fisher) and normalized to the luminescence of nontreated cells. Dose-response curves were fitted using the log (inhibitor) vs response variable slope 4-parameter fitting function of GraphPad Prism (GraphPad Software, Inc.). Data are shown as % relative cell viability versus molar compound concentration. Error bars indicate the standard deviation (SD) of triplicates. Geometric mean values of IC50's derived from multiple experiments were calculated.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	SK-CO-1 cells		CVCL_0626
Experiment 2 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.2&#1770.8 nM	High CEACAM5 expression (CEACAM5 +++)
Method Description	Human cancer cell lines were obtained from the American Type Culture Collection (CEA5-positive: SK-CO-1, MKN-45, LS174T; CEA5-negative MDA-MB-231) and maintained according to standard culture conditions (SK-CO-1, MKN-45: 37 °C, 5% CO2, 95% humidity; LS174T, MDA-MB-231: 37 °C, 10% CO2, 95% humidity). SK-CO-1 cells were cultured in Minimum Essential Medium Eagle (Sigma-Aldrich, FG0325) including l-alanylglutamine supplemented with 10% fetal bovine serum (FBS) and 1 mM sodium pyruvate. LS174T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich, FG0435) including l-alanyl-glutamine supplemented with 10% FBS, 1 mM sodium pyruvate, and 1% (v/v) nonessential amino acid 100× mix (Sigma-Aldrich, M7145). MDA-MBA-231 cells were cultured in DMEM including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. MKN-45 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 (Sigma-Aldrich, FG1215) medium including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. For subculturing, adherent cells were detached by the addition of TrypLE Express (1×) (Gibco, 12604-013), diluted with fresh medium, and transferred into a new culturing flask. For the evaluation of exatecan and exatecan conjugates, 90 uL of viable cell (vc) suspension was seeded into 96-well plates (SK-CO-1 2,500 vc/well, MKN-45 500 vc/well, LS174T 2,500 vc/well, MDA-MB-231 1,500 vc/well) followed by incubation (37 °C, 5 or 10% CO2) in a humid chamber overnight. Test compounds were formulated at a 10-fold starting concentration, prepared in serial dilution (1:4), and 10 uL was added to cells for each dilution in triplicates. The cell viability was determined after 6 days using the CellTiter-Glo reagent (Promega, G7573) according to the manufacturer's instructions. Luminescence values were measured by using a Varioskan plate reader (Thermo Fisher) and normalized to the luminescence of nontreated cells. Dose-response curves were fitted using the log (inhibitor) vs response variable slope 4-parameter fitting function of GraphPad Prism (GraphPad Software, Inc.). Data are shown as % relative cell viability versus molar compound concentration. Error bars indicate the standard deviation (SD) of triplicates. Geometric mean values of IC50's derived from multiple experiments were calculated.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 3 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.35&#1770.05 nM	High CEACAM5 expression (CEACAM5 +++)
Method Description	Human cancer cell lines were obtained from the American Type Culture Collection (CEA5-positive: SK-CO-1, MKN-45, LS174T; CEA5-negative MDA-MB-231) and maintained according to standard culture conditions (SK-CO-1, MKN-45: 37 °C, 5% CO2, 95% humidity; LS174T, MDA-MB-231: 37 °C, 10% CO2, 95% humidity). SK-CO-1 cells were cultured in Minimum Essential Medium Eagle (Sigma-Aldrich, FG0325) including l-alanylglutamine supplemented with 10% fetal bovine serum (FBS) and 1 mM sodium pyruvate. LS174T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich, FG0435) including l-alanyl-glutamine supplemented with 10% FBS, 1 mM sodium pyruvate, and 1% (v/v) nonessential amino acid 100× mix (Sigma-Aldrich, M7145). MDA-MBA-231 cells were cultured in DMEM including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. MKN-45 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 (Sigma-Aldrich, FG1215) medium including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. For subculturing, adherent cells were detached by the addition of TrypLE Express (1×) (Gibco, 12604-013), diluted with fresh medium, and transferred into a new culturing flask. For the evaluation of exatecan and exatecan conjugates, 90 uL of viable cell (vc) suspension was seeded into 96-well plates (SK-CO-1 2,500 vc/well, MKN-45 500 vc/well, LS174T 2,500 vc/well, MDA-MB-231 1,500 vc/well) followed by incubation (37 °C, 5 or 10% CO2) in a humid chamber overnight. Test compounds were formulated at a 10-fold starting concentration, prepared in serial dilution (1:4), and 10 uL was added to cells for each dilution in triplicates. The cell viability was determined after 6 days using the CellTiter-Glo reagent (Promega, G7573) according to the manufacturer's instructions. Luminescence values were measured by using a Varioskan plate reader (Thermo Fisher) and normalized to the luminescence of nontreated cells. Dose-response curves were fitted using the log (inhibitor) vs response variable slope 4-parameter fitting function of GraphPad Prism (GraphPad Software, Inc.). Data are shown as % relative cell viability versus molar compound concentration. Error bars indicate the standard deviation (SD) of triplicates. Geometric mean values of IC50's derived from multiple experiments were calculated.    Click to Show/Hide
In Vitro Model	Gastric adenocarcinoma	MKN-45 cells		CVCL_0434
Experiment 4 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	31.7&#1779.2 nM	Negative CEACAM5 expression (CEACAM5-)
Method Description	Human cancer cell lines were obtained from the American Type Culture Collection (CEA5-positive: SK-CO-1, MKN-45, LS174T; CEA5-negative MDA-MB-231) and maintained according to standard culture conditions (SK-CO-1, MKN-45: 37 °C, 5% CO2, 95% humidity; LS174T, MDA-MB-231: 37 °C, 10% CO2, 95% humidity). SK-CO-1 cells were cultured in Minimum Essential Medium Eagle (Sigma-Aldrich, FG0325) including l-alanylglutamine supplemented with 10% fetal bovine serum (FBS) and 1 mM sodium pyruvate. LS174T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich, FG0435) including l-alanyl-glutamine supplemented with 10% FBS, 1 mM sodium pyruvate, and 1% (v/v) nonessential amino acid 100× mix (Sigma-Aldrich, M7145). MDA-MBA-231 cells were cultured in DMEM including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. MKN-45 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 (Sigma-Aldrich, FG1215) medium including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. For subculturing, adherent cells were detached by the addition of TrypLE Express (1×) (Gibco, 12604-013), diluted with fresh medium, and transferred into a new culturing flask. For the evaluation of exatecan and exatecan conjugates, 90 uL of viable cell (vc) suspension was seeded into 96-well plates (SK-CO-1 2,500 vc/well, MKN-45 500 vc/well, LS174T 2,500 vc/well, MDA-MB-231 1,500 vc/well) followed by incubation (37 °C, 5 or 10% CO2) in a humid chamber overnight. Test compounds were formulated at a 10-fold starting concentration, prepared in serial dilution (1:4), and 10 uL was added to cells for each dilution in triplicates. The cell viability was determined after 6 days using the CellTiter-Glo reagent (Promega, G7573) according to the manufacturer's instructions. Luminescence values were measured by using a Varioskan plate reader (Thermo Fisher) and normalized to the luminescence of nontreated cells. Dose-response curves were fitted using the log (inhibitor) vs response variable slope 4-parameter fitting function of GraphPad Prism (GraphPad Software, Inc.). Data are shown as % relative cell viability versus molar compound concentration. Error bars indicate the standard deviation (SD) of triplicates. Geometric mean values of IC50's derived from multiple experiments were calculated.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.2&#1770.04 nM	High CEACAM5 expression (CEACAM5 +++)
Method Description	Human cancer cell lines were obtained from the American Type Culture Collection (CEA5-positive: SK-CO-1, MKN-45, LS174T; CEA5-negative MDA-MB-231) and maintained according to standard culture conditions (SK-CO-1, MKN-45: 37 °C, 5% CO2, 95% humidity; LS174T, MDA-MB-231: 37 °C, 10% CO2, 95% humidity). SK-CO-1 cells were cultured in Minimum Essential Medium Eagle (Sigma-Aldrich, FG0325) including l-alanylglutamine supplemented with 10% fetal bovine serum (FBS) and 1 mM sodium pyruvate. LS174T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich, FG0435) including l-alanyl-glutamine supplemented with 10% FBS, 1 mM sodium pyruvate, and 1% (v/v) nonessential amino acid 100× mix (Sigma-Aldrich, M7145). MDA-MBA-231 cells were cultured in DMEM including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. MKN-45 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 (Sigma-Aldrich, FG1215) medium including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. For subculturing, adherent cells were detached by the addition of TrypLE Express (1×) (Gibco, 12604-013), diluted with fresh medium, and transferred into a new culturing flask. For the evaluation of exatecan and exatecan conjugates, 90 uL of viable cell (vc) suspension was seeded into 96-well plates (SK-CO-1 2,500 vc/well, MKN-45 500 vc/well, LS174T 2,500 vc/well, MDA-MB-231 1,500 vc/well) followed by incubation (37 °C, 5 or 10% CO2) in a humid chamber overnight. Test compounds were formulated at a 10-fold starting concentration, prepared in serial dilution (1:4), and 10 uL was added to cells for each dilution in triplicates. The cell viability was determined after 6 days using the CellTiter-Glo reagent (Promega, G7573) according to the manufacturer's instructions. Luminescence values were measured by using a Varioskan plate reader (Thermo Fisher) and normalized to the luminescence of nontreated cells. Dose-response curves were fitted using the log (inhibitor) vs response variable slope 4-parameter fitting function of GraphPad Prism (GraphPad Software, Inc.). Data are shown as % relative cell viability versus molar compound concentration. Error bars indicate the standard deviation (SD) of triplicates. Geometric mean values of IC50's derived from multiple experiments were calculated.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	SK-CO-1 cells		CVCL_0626
Experiment 2 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.28&#1770.05 nM	High CEACAM5 expression (CEACAM5 +++)
Method Description	Human cancer cell lines were obtained from the American Type Culture Collection (CEA5-positive: SK-CO-1, MKN-45, LS174T; CEA5-negative MDA-MB-231) and maintained according to standard culture conditions (SK-CO-1, MKN-45: 37 °C, 5% CO2, 95% humidity; LS174T, MDA-MB-231: 37 °C, 10% CO2, 95% humidity). SK-CO-1 cells were cultured in Minimum Essential Medium Eagle (Sigma-Aldrich, FG0325) including l-alanylglutamine supplemented with 10% fetal bovine serum (FBS) and 1 mM sodium pyruvate. LS174T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich, FG0435) including l-alanyl-glutamine supplemented with 10% FBS, 1 mM sodium pyruvate, and 1% (v/v) nonessential amino acid 100× mix (Sigma-Aldrich, M7145). MDA-MBA-231 cells were cultured in DMEM including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. MKN-45 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 (Sigma-Aldrich, FG1215) medium including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. For subculturing, adherent cells were detached by the addition of TrypLE Express (1×) (Gibco, 12604-013), diluted with fresh medium, and transferred into a new culturing flask. For the evaluation of exatecan and exatecan conjugates, 90 uL of viable cell (vc) suspension was seeded into 96-well plates (SK-CO-1 2,500 vc/well, MKN-45 500 vc/well, LS174T 2,500 vc/well, MDA-MB-231 1,500 vc/well) followed by incubation (37 °C, 5 or 10% CO2) in a humid chamber overnight. Test compounds were formulated at a 10-fold starting concentration, prepared in serial dilution (1:4), and 10 uL was added to cells for each dilution in triplicates. The cell viability was determined after 6 days using the CellTiter-Glo reagent (Promega, G7573) according to the manufacturer's instructions. Luminescence values were measured by using a Varioskan plate reader (Thermo Fisher) and normalized to the luminescence of nontreated cells. Dose-response curves were fitted using the log (inhibitor) vs response variable slope 4-parameter fitting function of GraphPad Prism (GraphPad Software, Inc.). Data are shown as % relative cell viability versus molar compound concentration. Error bars indicate the standard deviation (SD) of triplicates. Geometric mean values of IC50's derived from multiple experiments were calculated.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 3 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.53&#1770.09 nM	Negative CEACAM5 expression (CEACAM5-)
Method Description	Human cancer cell lines were obtained from the American Type Culture Collection (CEA5-positive: SK-CO-1, MKN-45, LS174T; CEA5-negative MDA-MB-231) and maintained according to standard culture conditions (SK-CO-1, MKN-45: 37 °C, 5% CO2, 95% humidity; LS174T, MDA-MB-231: 37 °C, 10% CO2, 95% humidity). SK-CO-1 cells were cultured in Minimum Essential Medium Eagle (Sigma-Aldrich, FG0325) including l-alanylglutamine supplemented with 10% fetal bovine serum (FBS) and 1 mM sodium pyruvate. LS174T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich, FG0435) including l-alanyl-glutamine supplemented with 10% FBS, 1 mM sodium pyruvate, and 1% (v/v) nonessential amino acid 100× mix (Sigma-Aldrich, M7145). MDA-MBA-231 cells were cultured in DMEM including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. MKN-45 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 (Sigma-Aldrich, FG1215) medium including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. For subculturing, adherent cells were detached by the addition of TrypLE Express (1×) (Gibco, 12604-013), diluted with fresh medium, and transferred into a new culturing flask. For the evaluation of exatecan and exatecan conjugates, 90 uL of viable cell (vc) suspension was seeded into 96-well plates (SK-CO-1 2,500 vc/well, MKN-45 500 vc/well, LS174T 2,500 vc/well, MDA-MB-231 1,500 vc/well) followed by incubation (37 °C, 5 or 10% CO2) in a humid chamber overnight. Test compounds were formulated at a 10-fold starting concentration, prepared in serial dilution (1:4), and 10 uL was added to cells for each dilution in triplicates. The cell viability was determined after 6 days using the CellTiter-Glo reagent (Promega, G7573) according to the manufacturer's instructions. Luminescence values were measured by using a Varioskan plate reader (Thermo Fisher) and normalized to the luminescence of nontreated cells. Dose-response curves were fitted using the log (inhibitor) vs response variable slope 4-parameter fitting function of GraphPad Prism (GraphPad Software, Inc.). Data are shown as % relative cell viability versus molar compound concentration. Error bars indicate the standard deviation (SD) of triplicates. Geometric mean values of IC50's derived from multiple experiments were calculated.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.7&#1770.24 nM	High CEACAM5 expression (CEACAM5 +++)
Method Description	Human cancer cell lines were obtained from the American Type Culture Collection (CEA5-positive: SK-CO-1, MKN-45, LS174T; CEA5-negative MDA-MB-231) and maintained according to standard culture conditions (SK-CO-1, MKN-45: 37 °C, 5% CO2, 95% humidity; LS174T, MDA-MB-231: 37 °C, 10% CO2, 95% humidity). SK-CO-1 cells were cultured in Minimum Essential Medium Eagle (Sigma-Aldrich, FG0325) including l-alanylglutamine supplemented with 10% fetal bovine serum (FBS) and 1 mM sodium pyruvate. LS174T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich, FG0435) including l-alanyl-glutamine supplemented with 10% FBS, 1 mM sodium pyruvate, and 1% (v/v) nonessential amino acid 100× mix (Sigma-Aldrich, M7145). MDA-MBA-231 cells were cultured in DMEM including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. MKN-45 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 (Sigma-Aldrich, FG1215) medium including l-alanylglutamine supplemented with 10% FBS and 1 mM sodium pyruvate. For subculturing, adherent cells were detached by the addition of TrypLE Express (1×) (Gibco, 12604-013), diluted with fresh medium, and transferred into a new culturing flask. For the evaluation of exatecan and exatecan conjugates, 90 uL of viable cell (vc) suspension was seeded into 96-well plates (SK-CO-1 2,500 vc/well, MKN-45 500 vc/well, LS174T 2,500 vc/well, MDA-MB-231 1,500 vc/well) followed by incubation (37 °C, 5 or 10% CO2) in a humid chamber overnight. Test compounds were formulated at a 10-fold starting concentration, prepared in serial dilution (1:4), and 10 uL was added to cells for each dilution in triplicates. The cell viability was determined after 6 days using the CellTiter-Glo reagent (Promega, G7573) according to the manufacturer's instructions. Luminescence values were measured by using a Varioskan plate reader (Thermo Fisher) and normalized to the luminescence of nontreated cells. Dose-response curves were fitted using the log (inhibitor) vs response variable slope 4-parameter fitting function of GraphPad Prism (GraphPad Software, Inc.). Data are shown as % relative cell viability versus molar compound concentration. Error bars indicate the standard deviation (SD) of triplicates. Geometric mean values of IC50's derived from multiple experiments were calculated.    Click to Show/Hide
In Vitro Model	Gastric adenocarcinoma	MKN-45 cells		CVCL_0434

Experiment 1 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.6 nM	High HER2 expression (HER2 +++)
Method Description	HCC-1954, JIMT-1 and MDA-MB-468 cells were plated in 24-well culture plates (5000, 5000 and 10,000 cells/well, respectively) and incubated for 24 h. Cells were then exposed to serial dilutions of trastuzumab, free exatecan, or Tras-Exa (DAR4) ADC. Cell viability was evaluated following 6 days of incubation using MTT (3 ug/mL, Sigma). MTT absorbance was measured at 570 nm using SpectraMax M5e multi-detection reader.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	HCC-1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	40 nM	Positive HER2 expression (HER2+++/++)
Method Description	HCC-1954, JIMT-1 and MDA-MB-468 cells were plated in 24-well culture plates (5000, 5000 and 10,000 cells/well, respectively) and incubated for 24 h. Cells were then exposed to serial dilutions of trastuzumab, free exatecan, or Tras-Exa (DAR4) ADC. Cell viability was evaluated following 6 days of incubation using MTT (3 ug/mL, Sigma). MTT absorbance was measured at 570 nm using SpectraMax M5e multi-detection reader.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	50 nM	Low HER2 expression (HER2+)
Method Description	HCC-1954, JIMT-1 and MDA-MB-468 cells were plated in 24-well culture plates (5000, 5000 and 10,000 cells/well, respectively) and incubated for 24 h. Cells were then exposed to serial dilutions of trastuzumab, free exatecan, or Tras-Exa (DAR4) ADC. Cell viability was evaluated following 6 days of incubation using MTT (3 ug/mL, Sigma). MTT absorbance was measured at 570 nm using SpectraMax M5e multi-detection reader.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.365 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.0 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	28.28 nM	High TROP2 expression (TROP2 +++)
Method Description	Panc 08.13, Panc 10.05, A375 and HCT116 cells were seeded in 96-well plate at a density of 5000 cells per well. After overnight adherence at 37 °C in a humidified incubator with 5 % CO2, drugs were added to the cells in a specific concentration gradient. After incubated at 37 °C, 5 % CO2 for 72h, cell viability was detected using the Cell Counting Kit-8 kit (Shandong Sparkjade Biotechnology Co., Ltd.), and the absorbance optical density (OD) values at 450 nm were read by a microplate reader (SpectraMax i3, MD, USA). The cell viability rate was calculated according to the following equation: viability % = (ODadministration - ODblank)/ (ODcontrol - ODblank) × 100 %. Olaparib and Adavosertib were purchased from MedChemExpress. KU-60019, Rabusertib, ML323, Berzosertib, RI-1 and AZD7648 were purchased from Selleck.    Click to Show/Hide
In Vitro Model	Pancreatic ductal adenocarcinoma	Panc 10.05 cells		CVCL_1639
Experiment 2 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	31.59 nM	High TROP2 expression (TROP2 +++)
Method Description	Panc 08.13, Panc 10.05, A375 and HCT116 cells were seeded in 96-well plate at a density of 5000 cells per well. After overnight adherence at 37 °C in a humidified incubator with 5 % CO2, drugs were added to the cells in a specific concentration gradient. After incubated at 37 °C, 5 % CO2 for 72h, cell viability was detected using the Cell Counting Kit-8 kit (Shandong Sparkjade Biotechnology Co., Ltd.), and the absorbance optical density (OD) values at 450 nm were read by a microplate reader (SpectraMax i3, MD, USA). The cell viability rate was calculated according to the following equation: viability % = (ODadministration - ODblank)/ (ODcontrol - ODblank) × 100 %. Olaparib and Adavosertib were purchased from MedChemExpress. KU-60019, Rabusertib, ML323, Berzosertib, RI-1 and AZD7648 were purchased from Selleck.    Click to Show/Hide
In Vitro Model	Pancreatic ductal adenocarcinoma	Panc 08.13 cells		CVCL_1638

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.003 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.003 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.004 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.004 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.005 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.005 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.008 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.008 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.013 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.018 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.018 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.019 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.019 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.019 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.019 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.022 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.027 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.027 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.028 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.028 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.042 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.042 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.119 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.119 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.17 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.1 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.222 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.222 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.236 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.236 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.372 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.6 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.373 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.373 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.382 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.2 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.465 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.0 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.465 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.20 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.92 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.0 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.92 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.19 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.365 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.18 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.07 nM	Positive HER2 expression (HER2+++/++)
Method Description	NCI-N87 (HER2+++)
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.117 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.0 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.117 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.21 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12.5 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	To investigate the cytotoxicity of the unconjugated small-molecule TOP1 inhibitors and ADCs, respective cells were incubated for 4 days (small molecules) and 7 days (ADCs) with increasing concentrations of small molecules (0.015-1,000 nmol/L) and ADCs (0.05-3 ug/mL) to generate a dose-response curve. Killing was analyzed using resazurin cell viability dye at a final concentration of 55 umol/L (Merck) by dividing the fluorescence from control cells in medium by the fluorescence of ADC-treated cells. Fluorescence emission at 590 nmol/L was measured on a microplate reader Infinite 200 Pro (Tecan Group Ltd.).    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal Effective Concentration (EC50)	97.6 ng/mL	Negative HER2 expression (HER2-)
Method Description	To investigate the cytotoxicity of the unconjugated small-molecule TOP1 inhibitors and ADCs, respective cells were incubated for 4 days (small molecules) and 7 days (ADCs) with increasing concentrations of small molecules (0.015-1,000 nmol/L) and ADCs (0.05-3 ug/mL) to generate a dose-response curve. Killing was analyzed using resazurin cell viability dye at a final concentration of 55 umol/L (Merck) by dividing the fluorescence from control cells in medium by the fluorescence of ADC-treated cells. Fluorescence emission at 590 nmol/L was measured on a microplate reader Infinite 200 Pro (Tecan Group Ltd.).    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	HCC-78 cells		CVCL_2061

Experiment 1 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal Effective Concentration (EC50)	15.5 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	To investigate the cytotoxicity of the unconjugated small-molecule TOP1 inhibitors and ADCs, respective cells were incubated for 4 days (small molecules) and 7 days (ADCs) with increasing concentrations of small molecules (0.015-1,000 nmol/L) and ADCs (0.05-3 ug/mL) to generate a dose-response curve. Killing was analyzed using resazurin cell viability dye at a final concentration of 55 umol/L (Merck) by dividing the fluorescence from control cells in medium by the fluorescence of ADC-treated cells. Fluorescence emission at 590 nmol/L was measured on a microplate reader Infinite 200 Pro (Tecan Group Ltd.).    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal Effective Concentration (EC50)	144.1 ng/mL	Negative HER2 expression (HER2-)
Method Description	To investigate the cytotoxicity of the unconjugated small-molecule TOP1 inhibitors and ADCs, respective cells were incubated for 4 days (small molecules) and 7 days (ADCs) with increasing concentrations of small molecules (0.015-1,000 nmol/L) and ADCs (0.05-3 ug/mL) to generate a dose-response curve. Killing was analyzed using resazurin cell viability dye at a final concentration of 55 umol/L (Merck) by dividing the fluorescence from control cells in medium by the fluorescence of ADC-treated cells. Fluorescence emission at 590 nmol/L was measured on a microplate reader Infinite 200 Pro (Tecan Group Ltd.).    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	HCC-78 cells		CVCL_2061

Experiment 1 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal Effective Concentration (EC50)	18 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	To investigate the cytotoxicity of the unconjugated small-molecule TOP1 inhibitors and ADCs, respective cells were incubated for 4 days (small molecules) and 7 days (ADCs) with increasing concentrations of small molecules (0.015-1,000 nmol/L) and ADCs (0.05-3 ug/mL) to generate a dose-response curve. Killing was analyzed using resazurin cell viability dye at a final concentration of 55 umol/L (Merck) by dividing the fluorescence from control cells in medium by the fluorescence of ADC-treated cells. Fluorescence emission at 590 nmol/L was measured on a microplate reader Infinite 200 Pro (Tecan Group Ltd.).    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal Effective Concentration (EC50)	121.2 ng/mL	Negative HER2 expression (HER2-)
Method Description	To investigate the cytotoxicity of the unconjugated small-molecule TOP1 inhibitors and ADCs, respective cells were incubated for 4 days (small molecules) and 7 days (ADCs) with increasing concentrations of small molecules (0.015-1,000 nmol/L) and ADCs (0.05-3 ug/mL) to generate a dose-response curve. Killing was analyzed using resazurin cell viability dye at a final concentration of 55 umol/L (Merck) by dividing the fluorescence from control cells in medium by the fluorescence of ADC-treated cells. Fluorescence emission at 590 nmol/L was measured on a microplate reader Infinite 200 Pro (Tecan Group Ltd.).    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	HCC-78 cells		CVCL_2061

Experiment 1 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal Effective Concentration (EC50)	114.7 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	To investigate the cytotoxicity of the unconjugated small-molecule TOP1 inhibitors and ADCs, respective cells were incubated for 4 days (small molecules) and 7 days (ADCs) with increasing concentrations of small molecules (0.015-1,000 nmol/L) and ADCs (0.05-3 ug/mL) to generate a dose-response curve. Killing was analyzed using resazurin cell viability dye at a final concentration of 55 umol/L (Merck) by dividing the fluorescence from control cells in medium by the fluorescence of ADC-treated cells. Fluorescence emission at 590 nmol/L was measured on a microplate reader Infinite 200 Pro (Tecan Group Ltd.).    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 3000 ng/mL	Negative HER2 expression (HER2-)
Method Description	To investigate the cytotoxicity of the unconjugated small-molecule TOP1 inhibitors and ADCs, respective cells were incubated for 4 days (small molecules) and 7 days (ADCs) with increasing concentrations of small molecules (0.015-1,000 nmol/L) and ADCs (0.05-3 ug/mL) to generate a dose-response curve. Killing was analyzed using resazurin cell viability dye at a final concentration of 55 umol/L (Merck) by dividing the fluorescence from control cells in medium by the fluorescence of ADC-treated cells. Fluorescence emission at 590 nmol/L was measured on a microplate reader Infinite 200 Pro (Tecan Group Ltd.).    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	HCC-78 cells		CVCL_2061

Experiment 1 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal Effective Concentration (EC50)	182.4 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	To investigate the cytotoxicity of the unconjugated small-molecule TOP1 inhibitors and ADCs, respective cells were incubated for 4 days (small molecules) and 7 days (ADCs) with increasing concentrations of small molecules (0.015-1,000 nmol/L) and ADCs (0.05-3 ug/mL) to generate a dose-response curve. Killing was analyzed using resazurin cell viability dye at a final concentration of 55 umol/L (Merck) by dividing the fluorescence from control cells in medium by the fluorescence of ADC-treated cells. Fluorescence emission at 590 nmol/L was measured on a microplate reader Infinite 200 Pro (Tecan Group Ltd.).    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 3000 ng/mL	Negative HER2 expression (HER2-)
Method Description	To investigate the cytotoxicity of the unconjugated small-molecule TOP1 inhibitors and ADCs, respective cells were incubated for 4 days (small molecules) and 7 days (ADCs) with increasing concentrations of small molecules (0.015-1,000 nmol/L) and ADCs (0.05-3 ug/mL) to generate a dose-response curve. Killing was analyzed using resazurin cell viability dye at a final concentration of 55 umol/L (Merck) by dividing the fluorescence from control cells in medium by the fluorescence of ADC-treated cells. Fluorescence emission at 590 nmol/L was measured on a microplate reader Infinite 200 Pro (Tecan Group Ltd.).    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	HCC-78 cells		CVCL_2061

Experiment 1 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal Effective Concentration (EC50)	251 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	To investigate the cytotoxicity of the unconjugated small-molecule TOP1 inhibitors and ADCs, respective cells were incubated for 4 days (small molecules) and 7 days (ADCs) with increasing concentrations of small molecules (0.015-1,000 nmol/L) and ADCs (0.05-3 ug/mL) to generate a dose-response curve. Killing was analyzed using resazurin cell viability dye at a final concentration of 55 umol/L (Merck) by dividing the fluorescence from control cells in medium by the fluorescence of ADC-treated cells. Fluorescence emission at 590 nmol/L was measured on a microplate reader Infinite 200 Pro (Tecan Group Ltd.).    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 3000 ng/mL	Negative HER2 expression (HER2-)
Method Description	To investigate the cytotoxicity of the unconjugated small-molecule TOP1 inhibitors and ADCs, respective cells were incubated for 4 days (small molecules) and 7 days (ADCs) with increasing concentrations of small molecules (0.015-1,000 nmol/L) and ADCs (0.05-3 ug/mL) to generate a dose-response curve. Killing was analyzed using resazurin cell viability dye at a final concentration of 55 umol/L (Merck) by dividing the fluorescence from control cells in medium by the fluorescence of ADC-treated cells. Fluorescence emission at 590 nmol/L was measured on a microplate reader Infinite 200 Pro (Tecan Group Ltd.).    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	HCC-78 cells		CVCL_2061

Experiment 1 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal Effective Concentration (EC50)	265 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	To investigate the cytotoxicity of the unconjugated small-molecule TOP1 inhibitors and ADCs, respective cells were incubated for 4 days (small molecules) and 7 days (ADCs) with increasing concentrations of small molecules (0.015-1,000 nmol/L) and ADCs (0.05-3 ug/mL) to generate a dose-response curve. Killing was analyzed using resazurin cell viability dye at a final concentration of 55 umol/L (Merck) by dividing the fluorescence from control cells in medium by the fluorescence of ADC-treated cells. Fluorescence emission at 590 nmol/L was measured on a microplate reader Infinite 200 Pro (Tecan Group Ltd.).    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 3000 ng/mL	Negative HER2 expression (HER2-)
Method Description	To investigate the cytotoxicity of the unconjugated small-molecule TOP1 inhibitors and ADCs, respective cells were incubated for 4 days (small molecules) and 7 days (ADCs) with increasing concentrations of small molecules (0.015-1,000 nmol/L) and ADCs (0.05-3 ug/mL) to generate a dose-response curve. Killing was analyzed using resazurin cell viability dye at a final concentration of 55 umol/L (Merck) by dividing the fluorescence from control cells in medium by the fluorescence of ADC-treated cells. Fluorescence emission at 590 nmol/L was measured on a microplate reader Infinite 200 Pro (Tecan Group Ltd.).    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	HCC-78 cells		CVCL_2061

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 9.96%
Method Description	Ceralasertib=25 mg/kg.
In Vivo Model	Colon cancer CDX model
In Vitro Model	Colon cancer	HCT 116 cells		CVCL_0291
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 42.76%
Method Description	Ceralasertib=25 mg/kg.
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 56.70%
Method Description	CBX-12=5 mg/kg.
In Vivo Model	Colon cancer CDX model
In Vitro Model	Colon cancer	Colon cancer cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76.32%
Method Description	CBX-12=10 mg/kg.
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 81.22%
Method Description	Ceralasertib=25 mg/kg + CBX-12=5 mg/kg.
In Vivo Model	Colon cancer CDX model
In Vitro Model	Colon cancer	Colon cancer cells		Homo sapiens
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.40%
Method Description	Ceralasertib=25 mg/kg + CBX-12=10 mg/kg.
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Ref 1	TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Mol Cancer Ther. 2022 Jul 5;21(7):1090-1102.
Ref 2	A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Ref 3	IBI343 Combined with Chemotherapy in Advanced Pancreatic Cancer
Ref 4	A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma
Ref 5	Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Ref 6	Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ref 7	Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Ref 8	Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors, NCT05579366
Ref 9	Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Ref 10	A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
Ref 11	A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Ref 12	First in Human Study of TUB-030 in Patients with Advanced Solid Tumors
Ref 13	FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ref 14	Anti-CEACAM5 ADC M9140 in Chinese Participants With Solid Tumors (PROCEADE-CRC-02)
Ref 15	Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Ref 16	Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors
Ref 17	AMT-253 in Patients With Advanced Solid Tumours
Ref 18	AMT-253 in Patients With Selected Advanced Solid Tumours
Ref 19	PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)
Ref 20	Phase 1/2 Study of PRO1160 in Patients With Renal Cell Carcinoma (RCC), Nasopharyngeal Carcinoma (NPC), or Non-Hodgkin Lymphoma (NHL), NCT05721222
Ref 21	Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection
Ref 22	Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Ref 23	A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors
Ref 24	Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Ref 25	A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Ref 26	A Study of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Ref 27	A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Ref 28	To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors
Ref 29	AMT-562 in Patients With Selected Advanced Solid Tumors
Ref 30	Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009
Ref 31	A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
Ref 32	Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients
Ref 33	A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors
Ref 34	AMT-676 in Patients With Advanced Solid Tumors
Ref 35	A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009 in Patients With Advanced Solid Tumours, NCT05405621
Ref 36	A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of BAT8006 for Injection in Patients With Advanced Solid Tumors, NCT05378737
Ref 37	AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors. Mol Cancer Ther. 2023 Jun 11:MCT-23-0198. doi: 10.1158/1535-7163.MCT-23-0198. Online ahead of print.
Ref 38	Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discov. 2023 Apr 3;13(4):950-973. doi: 10.1158/2159-8290.CD-22-1368.
Ref 39	Antibody-drug conjugates
Ref 40	Enhancing the bystander effect of antibody-drug conjugate by using a novel caspase-3 cleavable peptide linker to overcome tumor heterogeneity
Ref 41	Preparation method and application of antibody drug conjugate
Ref 42	Generation and Characterization of Iduronidase-Cleavable ADCs
Ref 43	Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker
Ref 44	Camptothecin analogs conjugated to glutamine residues in proteins and their uses
Ref 45	Anti-ROR1 antibodies and antibody conjugates, compositions comprising Anti-ROR1 antibodies or antibody conjugates, and methods of making and using Anti-ROR1 antibodies and antibody conjugates
Ref 46	Exploiting synthetic lethality in PDAC with antibody drug conjugates and ATR inhibition
Ref 47	Anti-ROR1 antibodies and antibody conjugates, compositions comprising Anti-ROR1 antibodies or antibody conjugates, and methods of making and using Anti-ROR1 antibodies and antibody conjugates
Ref 48	Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates